Somewhat Positive Media Coverage Somewhat Unlikely to Impact Proteon Therapeutics (PRTO) Share Price
News stories about Proteon Therapeutics (NASDAQ:PRTO) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteon Therapeutics earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.3727951411684 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Proteon Therapeutics (PRTO) opened at 1.60 on Wednesday. The firm has a 50-day moving average price of $1.36 and a 200-day moving average price of $1.43. Proteon Therapeutics has a 52 week low of $1.10 and a 52 week high of $11.45. The company’s market capitalization is $28.19 million.
Proteon Therapeutics (NASDAQ:PRTO) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.11. Analysts anticipate that Proteon Therapeutics will post ($1.52) EPS for the current fiscal year.
A number of analysts recently issued reports on PRTO shares. Zacks Investment Research lowered Proteon Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Cowen and Company reiterated a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday, August 8th. HC Wainwright set a $2.00 price objective on Proteon Therapeutics and gave the company a “hold” rating in a research note on Wednesday, August 9th. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Proteon Therapeutics in a research note on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Proteon Therapeutics has a consensus rating of “Hold” and an average price target of $8.00.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.